DOCSLIB.ORG

Supplementary Table S1. Kinase Selectivity of MPI-0479605. (A)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table S1. Kinase Selectivity of MPI-0479605. (A) A B In-house kinase profiling Invitrogen SelectScreen Profiling % % % Kinase IC50 ( M) Kinase IC50 ( M) inhibition inhibition inhibition AKT3 >5 IKK-epsilon >5 Kinase at 500 nM Kinase at 500 nM Kinase at 500 nM ALK 0.26 INSR 0.38 ABL1 7 GRK6 -7 PAK1 4 AUR-A >5 JAK1 >5 GRK2 4 HCK 7 PASK 6 AUR-B >5 JNK1 0.11 AKT1 2 HIPK2 9 PHKG1 8 AUR-C >5 MEK1 >5 AXL 6 HIPK4 -6 PRKCB1 -2 B-RAF 3.2 MST4 >5 BMX 14 IGF1R 37 PRKCE 0 CDK1 >5 NEK2 >5 BRSK1 -9 IRAK4 0 PRKCG 3 CDK2 >5 PDK1 >5 CAMK2D -1 ITK 9 PRKCI -2 CDK6 >5 PKA >5 CDC42 BPA 0 LCK 29 PRKCN 6 CHK1 >5 PKC-delta >5 CDK5/p25 -1 LIMK1 17 PRKCZ -5 CHK2 >5 PLK1 >5 CSF1R 82 MAP2K1 11 PRKG2 2 C-MET >5 PLK4 3.3 CSK 1 MAP2K6 2 PTK6 15 C-SRC >5 ROCK2 >5 CSNK1D 10 MAP3K3 17 RET 11 DYRK2 >5 RSK2 >5 CSNK1G1 -1 MAP3K5 -1 RPS6KA2 23 ERK2 3.9 STK33 1.1 CSNK2A2 33 MAP3K8 12 RPS6KA5 2 FAK1 2.7 TAK1 >5 DCAMKL2 2 MAPK1 0 SGK2 4 FER 0.59 TAO1 >5 DYRK1B 1 MAPK11 2 SNF1LK2 3 FLT3 0.080 TBK1 >5 EEF2K 2 MAPK12 5 SRPK2 -3 HGK >5 TRKB >5 EGFR 14 MAPK3 -2 STK22B 11 IKK-alpha >5 YES1 >5 EPHA1 6 MAPK9 61 STK23 -1 IKK-beta >5 EPHA4 -10 MAPKAPK2 9 STK24 -2 EPHB1 -33 MARK4 3 STK25 0 ERBB2 5 MELK 6 TEK 6 FGFR1 15 MERTK 7 TYK2 10 FGR 17 MKNK1 2 TYRO3 -2 FLT4 15 MST1R 3 ZAP70 5 FRAP1 7 NEK1 1 GRK4 3 NEK4 -6 Supplementary Table S1. Kinase selectivity of MPI-0479605. (A). The effect of MPI- 0479605 on the activity of 42 protein kinases was determined. IC50 less than 1 M is highlighted in grey. (B) The inhibitory effect of 500 nM MPI-0479605 against a panel of kinases was determined using Z’-Lyte kinase assays (Invitrogen SelectScreen™ kinase profiling). Inhibition greater than 50% is highlighted in grey. MPI-0479605 Doubling GI50 (M) time (hrs) 3-day 7-day Cell Line A549 > 10 0.053 22.9 Colo205 0.105 0.044 23.8 DU-4475 > 10 0.042 45.0 DU-145 > 10 0.115 32.3 HCC827 > 10 0.054 28.0 HCT116 0.055 0.051 17.4 HT29 > 10 0.104 19.5 MDA MB 231 > 10 0.037 41.9 MiaPaCa2 > 10 0.055 40.0 NCI-H69 > 10 0.090 40.0 NCI-H460 0.178 0.091 17.8 NCI-N87 > 10 0.694 47.0 OPM2 > 10 0.0921 33.0 OVCAR-3 > 10 0.266 34.7 Supplementary Table S2. Effect of MPI-0479605 on cell viability. Cells were treated for 3 or 7 days with various concentrations of MPI-0479605 and the GI50 was determined. The reported time required for cells to double is also included. A B Mps1 WT Mps1 T676A MOCK Mps1 KD PPase untreated Mps1-pT676 Mps1-pT676 GFP-Mps1 Mps1 Endogenous Mps1 Mps1 GAPDH Supplementary Figure S1. Characterization of Mps1-pT676 antibody. (A) 50 ng recombinant Mps1 purified from E. Coli was pre-treated with or without lambda phosphatase. It was subsequently analyzed by Western blot with antibodies for Mps1 or phosphorylated Mps1 (Mps1-pT676). The Mps1-pT676 antibody only recognizes the phosphorylated form of recombinant Mps1. (B) HEK-293T cells were transfected with empty vector or plasmid encoding GFP-tagged Mps1 (wild-type (-WT), kinase-inactive (-KD), or phospho-acceptor mutant (-T676A)). After 48 hours, cell lysates were analyzed by Western blot with antibodies for Mps1, Mps1-pT676 or GAPDH. Loss of Mps1 kinase activity or the T676 phospho-acceptor site abolishes recognition of Mps1 by the Mps1-pT676 antibody. 40 30 EC50 = 71.3 nM 20 positive cells positive 10 % phospho-histone H3 0 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 [MPI-0479605], (M) Supplementary Figure S2. MPI-0479605 abrogates nocodazole-induced mitotic arrest. Nocodazole-arrested HeLa cells were treated with DMSO or increasing concentrations of MPI- 0479605 for 4 hours and subsequently stained for phosphohistone H3 (pHH3). Data are plotted as the percentage of cells that stained positive for pHH3 relative to the DMSO control sample. O O S HN N CH 3 N N N N N N H H O H C 3 Ispinesib 5-fluorouracil MPI-0485812 Supplementary Figure S3. Compound structures. HCT116 (p53WT) Colo-205 (p53Mut) 3 8 Vehicle Vehicle Z-VAD-FMK Z-VAD-FMK 6 2 4 1 (Fold Increase) (Fold Increase) 2 Caspase 3/7 Caspase 3/7 0 0 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 MPI-0479605, M MPI-0479605, M HCT116 (p53WT) Colo-205 (p53Mut) 150 150 Vehicle Vehicle GI50 = 84 nM GI50 = 100 nM Z-VAD-FMK Z-VAD-FMK 100 100 GI50 = 67 nM GI50 = 95 nM Viability 50 Viability 50 (% Vehicle Control) (% Vehicle Control) 0 0 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 10 -10 10 -9 10 -8 10 -7 10 -6 10 -5 10 -4 MPI-0479605, M MPI-0479605, M Supplementary Figure S4. Inhibition of caspase activity does not affect MPI-0479605- induced cell death. HCT-116 and Colo-205 cells were treated with MPI-0479605 in the absence or presence of 100 M Z-VAD-fmk. Caspase-3/7 activity (A, B) was determined after 48 hours while cell viability (C, D) was measured after 72 hours. 1000000 100000 30 mg/kg 150 mg/kg 10000 1000 (ng/mL) 100 concentration median plasma median 10 1 0 2 4 6 8 10 12 14 16 18 20 22 24 time (hr) Dose Cmax AUC (0-last) (mg/kg) (ng/L) (hr*ng/L) 30 18.3 30.1 150 76.5 786.4 Supplementary Figure S5. Pharmacokinetic analysis of MPI-0479605. Mice were dosed intraperitoneally with 30 or 150 mg/kg of MPI-0479605 and plasma concentrations of MPI- 0479605 were determined at the indicated times by mass spectrometry analysis. The dotted line represents the dose that is predicted to inhibit Mps1 in vivo based on cellular activity of MPI- 0479605. Colo-205 800 10 Vehicle MPI-0479605 (30mg/kg, QD) MPI-0479605 (150mg/kg,Q4D) 600 Ispinesib (10 mg/kg,Q4D) 0 400 % Change in % -10 Body Weight Body Tumor Volume 200 0 -20 0 5 10 15 20 25 0 5 10 15 20 25 Day Day Supplementary Figure S6. Effect of MPI-0479605 on xenograft tumor growth. Nude mice bearing Colo-205 tumors were treated (n=10 per group) intraperitoneally with MPI-0479605 at 30 mg/kg daily (QD) or at 150 mg/kg every fourth day (Q4D) for a period of 21 days. Ispinesib dosed Q4D at 10 mg/kg was used as a reference treatment. Median tumor volume (left) and body weight (right) were measured. There were two deaths at day 15 in the 150 mg/kg group. H2AX p53-S15 p53 GAPDH 9605 NOC 9605 NOC DMSO DMSO - Z-VAD-fmk Supplementary Figure S7. Effect of caspase inhibitor on MPI-0479605-induced phosphorylation of H2AX and p53. HCT-116 cells were pretreated with 100 M Z-VAD-fmk for 1 hour followed by treatment with 1 M MPI-0479605 for 48 hours. Cell lysates were analyzed by Western blot with antibodies for H2AX, phospho-p53(S15), p53 and GAPDH. Supplementary Materials and Methods In Vitro Kinase Assays and Selectivity Screening To measure Mps1 activity, 25 ng of recombinant, full-length enzyme was incubated in reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.01% Triton X-100 and 5 M Myelin basic protein (MBP)) containing vehicle (DMSO alone) or inhibitors. Forty M ATP (2xKm) was added with 1 Ci [-33P]ATP and the reaction was incubated at room temperature for 45 minutes. Reactions were terminated with 3% phosphoric acid and transferred to P81 filter plates. Samples were washed in 1% phosphoric acid and 33P radioactivity was measured on a TopCount scintillation reader (PerkinElmer). In-house kinase assays were all carried out at 2xKm ATP concentrations. MPI-0479605 (500 nM) was also screened against a larger kinase panel (SelectScreenTM Kinase Profiling; Invitrogen). Immunofluorescence Microscopy To measure phosphohistone H3 (pHH3), nocodazole-arrested cells were treated for 4 hours with MPI-0479605. Cells were fixed with 4% paraformaldehyde for 15 minutes at 37°C, permeabilized in 0.2% Triton-X 100 for 5 minutes, incubated with primary antibodies (rabbit polyclonal anti-phosphohistone H3 (diluted 1:200; Upstate) and mouse monoclonal anti- - tubulin (diluted 1:2000; Sigma)) for 45 min at 37oC, followed by a 45 min incubation with Alexa Fluor-conjugated secondary antibodies (Invitrogen). Cells were subsequently stained with Hoechst 33342 dye. The percentage of pHH3-positive cells was quantified by image analysis (BD Pathway High Content Imaging system). .
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Failures in Preclinical and Clinical Trials of C-Met Inhibitors: Evaluation of Pathway Activity As a Promising Selection Criterion
    www.oncotarget.com Oncotarget, 2019, Vol. 10, (No. 2), pp: 184-197 Research Paper Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion Veronica S. Hughes1 and Dietmar W. Siemann1 1University of Florida, Department of Radiation Oncology, UF Health Cancer Center, Gainesville, FL 32608, USA Correspondence to: Dietmar W. Siemann, email: [email protected] Keywords: cancer; c-Met; small molecule inhibitor; microenvironment; HGF Received: November 01, 2018 Accepted: December 20, 2018 Published: January 04, 2019 Copyright: Hughes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT C-Met is a frequently overexpressed or amplified receptor tyrosine kinase involved in metastatic-related functions, including migration, invasion, cell survival, and angiogenesis. Because of its role in cancer progression and metastasis, many inhibitors have been developed to target this pathway. Unfortunately, most c-Met inhibitor clinical trials have failed to show significant improvement in survival of cancer patients. In these trials tumor type, protein overexpression, or gene amplification are the primary selection criteria for patient inclusion. Our data show that none of these criteria are associated with c-Met pathway activation. Hence, it is conceivable that the majority of c-Met inhibitor clinical trial failures are the consequence of a lack of appropriate patient selection. Further complicating matters, c-Met inhibitors are routinely tested in preclinical studies in the presence of high levels of exogenous Hepatocyte Growth Factor (HGF), its activating ligand.
    [Show full text]
  • MARK4 with an Alzheimer's Disease-Related Mutation Promotes
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.20.107284; this version posted May 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. MARK4 with an Alzheimer’s disease-related mutation promotes tau hyperphosphorylation directly and indirectly and exacerbates neurodegeneration Toshiya Obaa, Taro Saitoa,b, Akiko Asadaa,b, Sawako Shimizua, Koichi M. Iijimac,d and Kanae Andoa,b, * aGraduate School of Science, Tokyo Metropolitan University, Tokyo 192-0397, Japan, bDepartment of Biological Sciences, School of Science, Tokyo Metropolitan University, Tokyo 192-0397, Japan, cDepartment of Alzheimer’s Disease Research, National Center for Geriatrics and Gerontology, Obu, Aichi 474-8511, Japan, dDepartment of Experimental Gerontology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi 467-8603, Japan *Corresponding author Kanae Ando, Ph.D. E-mail: [email protected] Running title: Mutant MARK4 enhances phospho-tau accumulation Abstract Accumulation of the microtubule-associated protein tau is associated with Alzheimer’s disease (AD). In AD brain, tau is abnormally phosphorylated at many sites, and phosphorylation at Ser262 and Ser356 play critical roles in tau accumulation and toxicity. Microtubule-affinity regulating kinase 4 (MARK4) phosphorylates tau at those sites, and a double de novo mutation in the linker region of MARK4, ΔG316E317InsD, is associated with an elevated risk of AD. However, it remains unclear how this mutation affects phosphorylation, aggregation, and accumulation of tau and tau-induced neurodegeneration. Here, we report that MARK4ΔG316E317D increases the abundance of highly phosphorylated, insoluble tau species and exacerbates neurodegeneration via Ser262/356-dependent and -independent mechanisms.
    [Show full text]
  • A Feed-Forward Cycle
    GMJ.2020;9:e1681 www.gmj.ir Received 2019-08-08 Revised 2019-11-11 Accepted 2019-11-24 Tau Abnormalities and Autophagic Defects in Neurodegenerative Disorders; A Feed-forward Cycle Nastaran Samimi 1, 2, Akiko Asada 3, 4, Kanae Ando 3, 4 1 Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran 2 Department of Brain and Cognitive Sciences, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran 3 Department of Biological Sciences, School of Science, Tokyo Metropolitan University, Tokyo, Japan 4 Graduate School of Science, Tokyo Metropolitan University, Tokyo, Japan Abstract Abnormal deposition of misfolded proteins is a neuropathological characteristic shared by many neurodegenerative disorders including Alzheimer’s disease (AD). Generation of excessive amounts of aggregated proteins and impairment of degradation systems for misfolded proteins such as autophagy can lead to accumulation of proteins in diseased neurons. Molecules that contribute to both these effects are emerging as critical players in disease pathogenesis. Furthermore, impairment of autophagy under disease conditions can be both a cause and a consequence of abnormal protein accumulation. Specifically, disease-causing proteins can impair autophagy, which further enhances the accumulation of abnormal proteins. In this short review, we focus on the relationship between the microtubule-associated protein tau and autophagy to highlight a feed-forward mechanism in disease pathogenesis. [GMJ.2020;9:e1681] DOI:10.31661/gmj.v9i0.1681 Keywords: Neurodegenerative Diseases; Tauopathy; Autophagy; Microtubule Binding Pro- tein; Tau; Phosphorylation; Vesicle Trafficking Tau phosphorylation in physiology and dis- However, tau detaches from microtubules and ease misfolds to form insoluble filaments in neuro- isfolded tau protein is deposited in a fibrillary tangles in the brains of patients with Mgroup of neurodegenerative diseases tauopathies [4-9].
    [Show full text]
  • Discovery of the Novel Autophagy Inhibitor Aumitin That Targets Mitochondrial Complex I
    Electronic Supplementary Material (ESI) for Chemical Science. This journal is © The Royal Society of Chemistry 2018 Discovery of the novel autophagy inhibitor Aumitin that targets mitochondrial complex I Lucas Robkea,b,c, Yushi Futamurad, Georgios Konstantinidise, Julian Wilkea,b, Harumi Aonod, Zhwan Mahmoudb, Nobumoto Watanabec,f, Yao-Wen Wue, Hiroyuki Osadac,d, Luca Laraiaa,g *, Herbert Waldmanna,b * a: Max-Planck-Institute of Molecular Physiology, department of Chemical Biology, Otto-Hahn-Str. 11, 44227 Dortmund (Germany); b: Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227 Dortmund (Germany); c: RIKEN-Max Planck Joint Research Division for Systems Chemical Biology, RIKEN CSRS, 2-1, Hirosawa, Wako, Saitama 351-0198 (Japan); d: Chemical Biology Research Group, RIKEN CSRS, 2-1, Hirosawa, Wako, Saitama 351-0198 (Japan); e: Chemical Genomics Centre of the Max-Planck-Society, Otto- Hahn-Str. 15, 44227 Dortmund (Germany); f: Bio-Active Compounds Discovery Research Unit, RIKEN CSRS, 2-1, Hirosawa, Wako, Saitama 351-0198 (Japan). g: present address: Department of Chemistry, Technical University of Denmark, Kemitorvet Building 207, Room 124, 2800 Kgs. Lyngby, Denmark. * [email protected], [email protected] SI-Table 1: Structure activity relationship of the di-aminopyrimidines. Starvation = starvation induced autophagy assay; Rapamycin = Rapamycin induced autophagy assay; Viability = survival assessed by means of an ADP-glow assay. > 10 = no inhibition at a test concentration of 10
    [Show full text]
  • A Calcium- and Calmodulin-Dependent Kinase I␣/ Microtubule Affinity Regulating Kinase 2 Signaling Cascade Mediates Calcium-Dependent Neurite Outgrowth
    The Journal of Neuroscience, April 18, 2007 • 27(16):4413–4423 • 4413 Cellular/Molecular A Calcium- and Calmodulin-Dependent Kinase I␣/ Microtubule Affinity Regulating Kinase 2 Signaling Cascade Mediates Calcium-Dependent Neurite Outgrowth Nataliya V. Uboha,1 Marc Flajolet,2 Angus C. Nairn,1,2 and Marina R. Picciotto1 1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508, and 2Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10021 Calcium is a critical regulator of neuronal differentiation and neurite outgrowth during development, as well as synaptic plasticity in adulthood. Calcium- and calmodulin-dependent kinase I (CaMKI) can regulate neurite outgrowth; however, the signal transduction cascades that lead to its physiological effects have not yet been elucidated. CaMKI␣ was therefore used as bait in a yeast two-hybrid assay and microtubule affinity regulating kinase 2 (MARK2)/Par-1b was identified as an interacting partner of CaMKI in three independent screens. The interaction between CaMKI and MARK2 was confirmed in vitro and in vivo by coimmunoprecipitation. CaMKI binds MARK2 within its kinase domain, but only if it is activated by calcium and calmodulin. Expression of CaMKI and MARK2 in Neuro-2A (N2a) cells and in primary hippocampal neurons promotes neurite outgrowth, an effect dependent on the catalytic activities of these enzymes. In addition, decreasing MARK2 activity blocks the ability of the calcium ionophore ionomycin to promote neurite outgrowth. Finally, CaMKI phosphorylates MARK2 on novel sites within its kinase domain. Mutation of these phosphorylation sites decreases both MARK2 kinase activity and its ability to promote neurite outgrowth.
    [Show full text]
  • Synthesis, Biological Evaluation and in Silico Studies of Certain Oxindole–Indole Conjugates As Anticancer CDK Inhibitors
    molecules Article Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole–Indole Conjugates as Anticancer CDK Inhibitors Tarfah Al-Warhi 1, Ahmed M. El Kerdawy 2,3 , Nada Aljaeed 1, Omnia E. Ismael 4, Rezk R. Ayyad 5, Wagdy M. Eldehna 6,* , Hatem A. Abdel-Aziz 7 and Ghada H. Al-Ansary 8,9,* 1 Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 12271, Saudi Arabia; [email protected] (T.A.-W.); [email protected] (N.A.) 2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt; [email protected] 3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, New Giza University, Newgiza, km 22 Cairo–Alexandria Desert Road, Cairo 12577, Egypt 4 Department of Biochemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt; [email protected] 5 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Cairo 11651, Egypt; [email protected] 6 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt 7 Department of Applied Organic Chemistry, National Research Center, Dokki, Giza 12622, Egypt; [email protected] 8 Department of Pharmaceutical Chemistry, Pharmacy Program, Batterejee Medical College, Jeddah 6231, Saudi Arabia 9 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo 11566, Egypt * Correspondence: [email protected] (W.M.E.); [email protected] (G.H.A.) Academic Editor: Sandra Gemma Received: 3 April 2020; Accepted: 23 April 2020; Published: 27 April 2020 Abstract: On account of their overexpression in a wide range of human malignancies, cyclin-dependent kinases (CDKs) are among the most validated cancer targets, and their inhibition has been featured as a valuable strategy for anticancer drug discovery.
    [Show full text]
  • New Insights in RBM20 Cardiomyopathy
    Current Heart Failure Reports (2020) 17:234–246 https://doi.org/10.1007/s11897-020-00475-x TRANSLATIONAL RESEARCH IN HEART FAILURE (J BACKS & M VAN DEN HOOGENHOF, SECTION EDITORS) New Insights in RBM20 Cardiomyopathy D. Lennermann1,2 & J. Backs1,2 & M. M. G. van den Hoogenhof1,2 Published online: 13 August 2020 # The Author(s) 2020 Abstract Purpose of Review This review aims to give an update on recent findings related to the cardiac splicing factor RNA-binding motif protein 20 (RBM20) and RBM20 cardiomyopathy, a form of dilated cardiomyopathy caused by mutations in RBM20. Recent Findings While most research on RBM20 splicing targets has focused on titin (TTN), multiple studies over the last years have shown that other splicing targets of RBM20 including Ca2+/calmodulin-dependent kinase IIδ (CAMK2D) might be critically involved in the development of RBM20 cardiomyopathy. In this regard, loss of RBM20 causes an abnormal intracellular calcium handling, which may relate to the arrhythmogenic presentation of RBM20 cardiomyopathy. In addition, RBM20 presents clinically in a highly gender-specific manner, with male patients suffering from an earlier disease onset and a more severe disease progression. Summary Further research on RBM20, and treatment of RBM20 cardiomyopathy, will need to consider both the multitude and relative contribution of the different splicing targets and related pathways, as well as gender differences. Keywords RBM20 . Dilated cardiomyopathy . CaMKIIδ . Calcium handling . Gender differences . Titin Introduction (ARVC), where a small number of genes account for most of the genetic causes, DCM-causing mutations have been ob- Dilated cardiomyopathy (DCM), as defined by left ventricular served in a variety of genes of diverse ontology [2].
    [Show full text]
  • A Missense Mutation in the RSRSP Stretch of Rbm20 Causes Dilated
    www.nature.com/scientificreports OPEN A missense mutation in the RSRSP stretch of Rbm20 causes dilated cardiomyopathy and atrial fbrillation in mice Kensuke Ihara1,2*, Tetsuo Sasano2, Yuichi Hiraoka3, Marina Togo‑Ohno4, Yurie Soejima5, Motoji Sawabe5, Megumi Tsuchiya6, Hidesato Ogawa6, Tetsushi Furukawa1 & Hidehito Kuroyanagi4* Dilated cardiomyopathy (DCM) is a fatal heart disease characterized by left ventricular dilatation and cardiac dysfunction. Recent genetic studies on DCM have identifed causative mutations in over 60 genes, including RBM20, which encodes a regulator of heart‑specifc splicing. DCM patients with RBM20 mutations have been reported to present with more severe cardiac phenotypes, including impaired cardiac function, atrial fbrillation (AF), and ventricular arrhythmias leading to sudden cardiac death, compared to those with mutations in the other genes. An RSRSP stretch of RBM20, a hotspot of missense mutations found in patients with idiopathic DCM, functions as a crucial part of its nuclear localization signals. However, the relationship between mutations in the RSRSP stretch and cardiac phenotypes has never been assessed in an animal model. Here, we show that Rbm20 mutant mice harboring a missense mutation S637A in the RSRSP stretch, mimicking that in a DCM patient, demonstrated severe cardiac dysfunction and spontaneous AF and ventricular arrhythmias mimicking the clinical state in patients. In contrast, Rbm20 mutant mice with frame‑shifting deletion demonstrated less severe phenotypes, although loss of RBM20‑dependent alternative splicing was indistinguishable. RBM20S637A protein cannot be localized to the nuclear speckles, but accumulated in cytoplasmic, perinuclear granule‑like structures in cardiomyocytes, which might contribute to the more severe cardiac phenotypes. Dilated cardiomyopathy (DCM) is a fatal cardiac disease characterized by enlargement of the cardiac chambers and impaired systolic function1.
    [Show full text]
  • Comprehensive Assessment of the Association of WNK4
    OPEN Comprehensive Assessment of the SUBJECT AREAS: Association of WNK4 Polymorphisms GENETICS RESEARCH RENOVASCULAR HYPERTENSION with Hypertension: Evidence from a EPIDEMIOLOGY Meta-Analysis Received Xiao-gang Guo1, Jie Ding1, Hui Xu1,2, Tian-ming Xuan1, Wei-quan Jin1, Xiang Yin1, Yun-peng Shang1, 22 April 2014 Fu-rong Zhang1, Jian-hua Zhu1 & Liang-rong Zheng1 Accepted 15 September 2014 1Department of Cardiology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China, Published 2Xiuzhou District, Gaozhao Street Community Health Service Center, Jiaxing 314031, China. 30 September 2014 The relationship between with-no-lysine [K] kinase 4 (WNK4) gene polymorphisms and hypertension has been widely investigated, However, the studies yielded contradictory results. To evaluate these inconclusive Correspondence and findings comprehensively, we therefore performed a meta-analysis. Ten articles encompassing 16 requests for materials independent case-control studies with 6089 hypertensive cases and 4881 normotensive controls were should be addressed to selected for this meta-analysis. Four WNK4 gene polymorphisms were identified (G1155942T, G1156666A, X.-G.G. (gxg22222@ T1155547C, and C6749T). The results showed statistically significant associations of G1155942T polymorphism (allelic genetic model: odds ration or OR51.62, 95% confidence interval or CI: 1.11–2.38, zju.edu.cn) P50.01; dominant model: OR51.85, 95% CI: 1.07–3.19, P50.03) and C6749T polymorphism (allele contrast: OR52.04, 95% CI: 1.60–2.59, P,0.01; dominant model: OR52.04, 95%CI: 1.59–2.62, P,0.01; and homozygous model: OR55.01, 95% CI: 1.29–19.54, P50.02) with hypertension risk. However, neither C1155547T nor G1156666A was associated significantly with hypertension susceptibility.
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]